Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Brazil's agricultural research agency gets cannabis research greenlight - 2How to watch the last supermoon of the year
- 3First foreign troop in new gang suppression force lands in Haiti to replace previous mission
- 4Some Americans say they'll go without health insurance as ACA rates spike
- 521 Incredibly Interesting Contemplations To Observe Consistently
- Spotify Wrapped and Apple Music Replay are here: Top songs, albums and artists of 2025
- Investigate the Excellence of Professional flowerbeds: A Virtual Local escort
- From Fledgling to Master: Self-awareness in a Side interest
- From Squid Game to Your Party! Six Entertaining Test Games That Will Have You in Join
- Washington resident contracts bird flu, first human case in U.S. since February
- Birds Will Flock To Your Birdbath When You Plant These Two Flowers Around It
- 6 Famous kind of practice on the planet
- If everyone on Earth sat in the ocean at once, how much would sea level rise?
- 6 Web-based Lawful Administrations: Extensive Surveys and Elements
